Last reviewed 2026-04-21 · How we verify

Acetylsalicylic Acid + clopidogrel + acenocoumarol

Acetylsalicylic Acid + clopidogrel + acenocoumarol is a Antiplatelet agent + Anticoagulant combination Small molecule drug developed by Hospital Universitari Vall d'Hebron Research Institute. It is currently FDA-approved for High-risk thrombotic conditions requiring intensive anticoagulation and antiplatelet therapy, Acute coronary syndrome with indication for anticoagulation.

This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: acetylsalicylic acid and clopidogrel block platelet aggregation, while acenocoumarol inhibits vitamin K-dependent clotting factors.

This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: acetylsalicylic acid and clopidogrel block platelet aggregation, while acenocoumarol inhibits vitamin K-dependent clotting factors. Used for High-risk thrombotic conditions requiring intensive anticoagulation and antiplatelet therapy, Acute coronary syndrome with indication for anticoagulation.

At a glance

Mechanism of action

Acetylsalicylic acid irreversibly inhibits cyclooxygenase and platelet aggregation. Clopidogrel is a P2Y12 receptor antagonist that prevents ADP-induced platelet activation. Acenocoumarol is a vitamin K antagonist that reduces synthesis of factors II, VII, IX, and X. Together, they provide dual antiplatelet and anticoagulant effects for intensive thromboprophylaxis.

Approved indications

• High-risk thrombotic conditions requiring intensive anticoagulation and antiplatelet therapy
• Acute coronary syndrome with indication for anticoagulation

Common side effects

• Bleeding/hemorrhage
• Gastrointestinal bleeding
• Intracranial hemorrhage
• Dyspepsia
• Bruising

Key clinical trials

• Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
• Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
• Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
• Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI (PHASE4)
• Anticoagulation in Stent Intervention (PHASE4)
• Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke
• Anticoagulant and Antiplatelet Agents in Patients Undergoing Vitreoretinal Surgery

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Acetylsalicylic Acid + clopidogrel + acenocoumarol CI brief — competitive landscape report
• Acetylsalicylic Acid + clopidogrel + acenocoumarol updates RSS · CI watch RSS
• Hospital Universitari Vall d'Hebron Research Institute portfolio CI

Frequently asked questions about Acetylsalicylic Acid + clopidogrel + acenocoumarol

Related

• Drug class: All Antiplatelet agent + Anticoagulant combination drugs
• Target: All drugs targeting Platelet cyclooxygenase (COX), P2Y12 receptor, Vitamin K-dependent clotting factors
• Manufacturer: Hospital Universitari Vall d'Hebron Research Institute — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for High-risk thrombotic conditions requiring intensive anticoagulation and antiplatelet therapy
• Indication: Drugs for Acute coronary syndrome with indication for anticoagulation
• Compare: Acetylsalicylic Acid + clopidogrel + acenocoumarol vs similar drugs
• Pricing: Acetylsalicylic Acid + clopidogrel + acenocoumarol cost, discount & access